“COPD: Disease Insights and Market Forecasts to 2024” report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of COPD disease in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan and the historical & forecasted market size, for COPD, drug wise in $ sales and patient numbers at global level and in the US, EU5 (Germany, France, Italy, Spain, UK), Australia and Canada till 2024.

Geographies covered:
US
Germany
France
Italy
Spain
UK
Japan
Australia
Canada

Drugs covered
Spiriva
Tudorza Pressair
Seebri Neohaler
Incruse Ellipta
Arcapta Neohaler/Onbrez
Striverdi Respimat
Advair/Seretide
Symbicort Turbuhaler
Breo Ellipta
Ultibro/Utibron
Anoro Ellipta
Brimica Genuair/Duaklir
Stiolto Respimat
Daliresp/Daxas
Trelegy Ellipta
Trimbow
Arnuity Ellipta
Bevespi Aerosphere
Lonhala Magnair
Revefenacin
PT010
Nucala
RPL554
Fasenra

Disease Indication Overview:
This section of the report gives the overview of COPD disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of COPD disease. Further details on the profile of COPD patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for COPD disease.

Epidemiology Forecasts to 2024:
This section of the report provides the overview of COPD diagnosed prevalent and treated patients in the US, EU5 and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Drugs Overview and Attribute Analysis:
This part of the report highlights the importance of factors influencing the physician prescription decisions in COPD disease including efficacy factors, Tolerability factors, Monitoring requirements and pricing factors.

The report further details the drugs prescribed or expected to be prescribed in COPD disease by the physicians in terms of details about the formulation, molecule, mode of administration and mechanism of action of the drugs, their patent and trial details and the expected impact of drug in the COPD market.

The report further conducts a detailed drug attribute analysis of the drugs currently prescribed or expected to be prescribed in the disease on the parameters of Efficacy, Safety and Tolerability, Convenience of Monitoring and Dosing and Drug’s coverage of the target patient pool.

Drugs and Market Forecast to 2024:
The report in its last section provides sales and patient numbers forecast for the overall COPD market and drug wise forecasts from 2015 till 2024 at Global level and in the US, EU5, Australia and Canada markets. The forecasts are developed based on the detailed drug attribute analysis, conducted by Pharmascroll, as shared in the previous section. It is important to note that the Forecasts conducted by Pharmascroll are not based on simple projections, and are developed meticulously based on a complex forecasting model, owned by Pharmascroll, using multiple assumptions related to launch dates of the products in the market, price of the products, adherence and compliance rates of the products, dosages of the products etc. The forecast models are at the country level and can be developed at the regional level as well.

Why Purchase the Report:
• Robust Market and Drug forecast available at country level
• Forecast in terms of both $ sales and Patient Numbers
• Current and Forecasted Drug treated and Diagnosed Prevalent Patient pool
• Detailed Drug Attribute analysis on multiple Clinical Parameters
• Multiple Countries coverage
• Current Marketed and Pipeline Drugs coverage
• Detailed Disease Insights coverage

To read more about the report please visit https://pharmascroll.com/copd-disease-insights-market-forecasts-2024/

To enquire about the report or to make a purchase for the report please write to [email protected]